ATRA (Atara Biotherapeutics) Cyclically Adjusted Book per Share: $125.06 (As of Mar. 2026)


ATRA Atara Biotherapeutics Inc ATRA
29 GF Score
Price $10.71
GF Value $1.56
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Atara Biotherapeutics Cyclically Adjusted Book per Share?

Atara Biotherapeutics ATRA +2.54% 29 Cyclically Adjusted Book per Share is $125.06 as of Mar. 2026. GuruFocus rates ATRA with a GF Score™ of 29/100 and a GF Value™ of $1.56 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Atara Biotherapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $-4.383. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $125.06 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Atara Biotherapeutics's average Cyclically Adjusted Book Growth Rate was -19.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Atara Biotherapeutics was -7.90% per year. The lowest was -7.90% per year. And the median was -7.90% per year.

As of today (2026-06-29), Atara Biotherapeutics's current stock price is $10.71. Atara Biotherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $125.06. Atara Biotherapeutics's Cyclically Adjusted PB Ratio of today is 0.09.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Atara Biotherapeutics was 0.78. The lowest was 0.03. And the median was 0.09.


Atara Biotherapeutics  (NAS:ATRA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Atara Biotherapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=10.71/125.06
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Atara Biotherapeutics was 0.78. The lowest was 0.03. And the median was 0.09.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Atara Biotherapeutics Cyclically Adjusted Book per Share Related Terms


Atara Biotherapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Atara Biotherapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics Cyclically Adjusted Book per Share Chart

Atara Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 168.76 161.38 158.96 131.88

Atara Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 154.96 150.95 141.82 131.88 125.06

ATRA vs ANIX, BMEA, PMN: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Cyclically Adjusted PB Ratio falls into.


ATRA
29GF Score
Atara Biotherapeutics Inc ATRA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atara Biotherapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Atara Biotherapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-4.383/330.2130*330.2130
=-4.383

Current CPI (Mar. 2026) = 330.2130.

Atara Biotherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 252.827 241.018 346.392
201609 234.144 241.428 320.250
201612 219.305 241.432 299.949
201703 200.287 243.801 271.276
201706 184.903 244.955 249.260
201709 168.265 246.819 225.118
201712 144.723 246.524 193.853
201803 250.105 249.554 330.942
201806 249.586 251.989 327.064
201809 220.731 252.439 288.736
201812 184.362 251.233 242.320
201903 153.312 254.202 199.155
201906 123.882 256.143 159.706
201909 147.086 256.759 189.165
201912 127.985 256.974 164.461
202003 107.219 258.115 137.168
202006 128.239 257.797 164.262
202009 114.579 260.280 145.365
202012 138.632 260.474 175.749
202103 118.655 264.877 147.923
202106 97.799 271.696 118.863
202109 87.734 274.310 105.614
202112 76.251 278.802 90.312
202203 60.042 287.504 68.961
202206 68.224 296.311 76.030
202209 49.305 296.808 54.854
202212 33.005 296.797 36.721
202303 16.820 301.836 18.401
202306 1.843 305.109 1.995
202309 -12.469 307.789 -13.377
202312 -23.305 306.746 -25.088
202403 -20.426 312.332 -21.595
202406 -22.608 314.175 -23.762
202409 -15.773 315.301 -16.519
202412 -16.604 315.605 -17.373
202503 -9.296 319.799 -9.599
202506 -5.022 322.561 -5.141
202509 -5.081 324.800 -5.166
202512 -5.257 324.054 -5.357
202603 -4.383 330.213 -4.383

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $125.06 mean?
Atara Biotherapeutics (ATRA) has a Cyclically Adjusted Book per Share of $125.06 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Atara Biotherapeutics and its competitors.
Is Atara Biotherapeutics' Cyclically Adjusted Book per Share too high?
Atara Biotherapeutics' current Cyclically Adjusted Book per Share is $125.06. Overall, Atara Biotherapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Cyclically Adjusted Book per Share compare to ANIX and BMEA?
Atara Biotherapeutics' Cyclically Adjusted Book per Share of $125.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Atara Biotherapeutics and its competitors. Atara Biotherapeutics's current Cyclically Adjusted Book per Share is $125.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.56, compared to a current price of $10.71 — trading 586.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is $125.06. Atara Biotherapeutics' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current Cyclically Adjusted Book per Share is $125.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atara Biotherapeutics (ATRA) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of $10.71 is trading 586.5% above its estimated GF Value™ of $1.56. GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.

Key valuation signals for ATRA:

  • Cyclically Adjusted Book per Share: $125.06
  • GF Value™: $1.56 vs. price of $10.71 (586.5% above fair value)
  • GF Score™: 29/100 with 7 warning signs

No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Atara Biotherapeutics Business Description

Other Exchanges 0HIY:UKAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
29GF Score

Get the complete analysis for ATRA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.71
Price
$1.56
GF Value